Table of Content

1. Key Insights

2. Cancer Cachexia (CC): Market Overview at a Glance
2.1. Total Market Share (%) Distribution of Cancer Cachexia in 2017
2.2. Total Market Share (%) Distribution of Cancer Cachexia in 2030

3. Executive summary

4. Organizations

5. Epidemiology and Market Methodology

6. Cancer Cachexia (CC): Disease Overview
6.1.1. Introduction
6.1.2. Stages of cachexia
6.1.3. Signs and Symptoms
6.1.4. Causes and Risk Factors
6.1.5. Clinical Manifestations
6.1.6. Pathophysiology
6.1.7. Diagnosis
6.1.8. Biomarkers of cachexia

7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Total prevalent cases of Cancer Cachexia in 7MM
7.3. Country Wise-Epidemiology of Cancer Cachexia
7.4. United States
7.5. Assumptions and Rationale
7.6. Total prevalent cases of Cancer Cachexia in the United States
7.7. Cancer Cachexia cases based on tumor type in the United States
7.8. Gender-Specific cases of Cancer Cachexia in the United States
7.9. EU5 Countries
7.10. Assumptions and Rationale
7.11. Germany
7.12. Total prevalent cases of Cancer Cachexia in Germany
7.13. Cancer Cachexia cases based on Tumor Type in Germany
7.14. Gender-Specific cases of Cancer Cachexia in Germany
7.15. France
7.16. Total prevalent cases of Cancer Cachexia in France
7.17. Cancer Cachexia cases based on Tumor Type in France
7.18. Gender-Specific cases of Cancer Cachexia in France
7.19. Italy
7.20. Total prevalent cases of Cancer Cachexia in Italy
7.21. Cancer Cachexia cases based on Tumor Type in Italy
7.22. Gender-Specific cases of Cancer Cachexia in Italy
7.23. Spain
7.24. Total prevalent cases of Cancer Cachexia in Spain
7.25. Cancer Cachexia cases based on Tumor Type in Spain
7.26. Gender-Specific cases of Cancer Cachexia in Spain
7.27. UK
7.28. Total prevalent cases of Cancer Cachexia in the United Kingdom
7.29. Cancer Cachexia cases based on tumor type in the United Kingdom
7.30. Gender-Specific cases of Cancer Cachexia in the United Kingdom
7.31. Japan
7.32. Assumptions and Rationale
7.33. Total prevalent cases of Cancer Cachexia in Japan
7.34. Cancer Cachexia cases based on tumor type in Japan
7.35. Gender-Specific cases of Cancer Cachexia in Japan

8. Current Treatment Practices
8.1. Treatment Algorithm
8.2. Treatment Guidelines- ESPEN

9. Unmet Needs

10. Emerging Therapies
10.1. Key Cross Competition
10.2. PPP011: Tetra Bio-Pharma
10.2.1. Drug Description
10.2.2. Other Developmental Activities
10.2.3. Clinical Development
10.2.4. Safety and Efficacy
10.2.5. Product Profile
10.3. Anamorelin: Helsinn Therapeutics/Ono Pharmaceutical
10.3.1. Product Description
10.3.2. Other Developmental Activities
10.3.3. Clinical Development
10.3.4. Safety and Efficacy
10.3.5. Product Profile
10.4. Macimorelin: AEterna Zentaris
10.4.1. Drug Description
10.4.2. Other Developmental Activities
10.4.3. Clinical Development
10.4.3.1. Product Profile
10.5. MT-102: Actimed Therapeutics/PsiOxus Therapeutics
10.5.1. Product Description
10.5.2. Clinical Development
10.5.3. Safety and Efficacy
10.5.4. Product Profile
10.6. PF-06946860: Pfizer
10.6.1. Product Description
10.6.2. Clinical Development
10.6.3. Product Profile
10.7. Xilonix plus Onivyde and 5FU: XBiotech/Janssen Pharmaceutical
10.7.1. Product Description
10.7.2. Other Developmental Activities
10.7.3. Clinical Development
10.7.4. Product Profile
10.8. Cannabics capsules: Cannabics Pharmaceuticals
10.8.1. Product Description
10.8.2. Clinical Development
10.8.3. Safety and Efficacy
10.8.4. Product Profile
10.9. NGM120: NGM Bio
10.9.1. Product Description
10.9.2. Other Developmental Activities
10.9.3. Clinical Development
10.9.4. Safety and Efficacy
10.9.5. Product Profile
10.10. ART27.13: Artelo BIOSCIENCES
10.10.1. Product Description
10.10.2. Other Developmental Activities
10.10.3. Safety and Efficacy
10.10.4. Product Profile

11. Cancer Cachexia: 7 Major Market Analysis
11.1. Key Findings
11.2. Market Size of Cancer Cachexia in 7MM
11.3. Seven Major Market Outlook
11.4. United States Market Size
11.5. Total market size of Cancer Cachexia in the United States
11.6. Total market size of Cancer Cachexia by Therapies in the United States
11.7. Germany
11.8. Total market size of Cancer Cachexia in Germany
11.9. Total market size of Cancer Cachexia by Therapies in Germany
11.10. France
11.11. Total market size of Cancer Cachexia in France
11.12. Total Market size of Cancer Cachexia by Therapies in France
11.13. Italy
11.14. Total market size of Cancer Cachexia in Italy
11.15. The total Market size of Cancer Cachexia by Therapies in Italy
11.16. Spain
11.17. Total Market Size of Cancer Cachexia in Spain
11.18. Total market size of Cancer Cachexia by Therapies in Spain
11.19. United Kingdom
11.20. Total market size of Cancer Cachexia in the United Kingdom
11.21. Total market size of Cancer Cachexia by Therapies in the UK
11.22. Japan
11.23. Total market size of Cancer Cachexia in Japan
11.24. Total market size of Cancer Cachexia by Therapies in Japan

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Market Access and Reimbursement

16. Case Study
16.1. A Case Report: Cancer Cachexia and Anabolic Interventions
16.2. Interdisciplinary Management of Cancer Cachexia
16.3. Monitoring Metastasis and Cachexia in a Patient with Breast Cancer: A Case Study

17. KOL Views

18. Bibliography

19. Appendix
19.1. Report Methodology

20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight



List of Figures


Figure 1: Epidemiology and Market Methodology
Figure 2: Total prevalent cases of Cancer Cachexia in 7MM (2017–2030)
Figure 3: Total prevalent cases of Cancer Cachexia in the US (2017–2030)
Figure 4: Cancer Cachexia cases based on tumor type in the US (2017–2030)
Figure 5: Gender-Specific cases of Cancer Cachexia in the US (2017–2030)
Figure 6: Total prevalent cases of Cancer Cachexia in Germany (2017–2030)
Figure 7: Cancer Cachexia cases based on Tumor Type in Germany (2017–2030)
Figure 8: Gender-Specific cases of Cancer Cachexia in Germany (2017–2030)
Figure 9: Total prevalent cases of Cancer Cachexia in France (2017–2030)
Figure 10: Cancer Cachexia cases based on Tumor Type in France (2017–2030)
Figure 11: Gender-Specific cases of Cancer Cachexia in France (2017–2030)
Figure 12: Total prevalent cases of Cancer Cachexia in Italy (2017–2030)
Figure 13: Cancer Cachexia cases based on Tumor Type in Italy (2017–2030)
Figure 14: Gender-Specific cases of Cancer Cachexia in Italy (2017–2030)
Figure 15: Total prevalent cases of Cancer Cachexia in Spain (2017–2030)
Figure 16: Cancer Cachexia cases based on Tumor Type in Spain (2017–2030)
Figure 17: Gender-Specific cases of Cancer Cachexia in Spain (2017–2030)
Figure 18: Total prevalent cases of Cancer Cachexia in the UK (2017–2030)
Figure 19: Cancer Cachexia cases based on Tumor Type in the UK (2017–2030)
Figure 20: Gender-Specific cases of Cancer Cachexia in the UK (2017–2030)
Figure 21: Total prevalent cases of Cancer Cachexia in Japan (2017–2030)
Figure 22: Cancer Cachexia cases based on tumor type in Japan (2017–2030)
Figure 23: Gender-Specific cases of Cancer Cachexia in Japan (2017–2030)
Figure 24: Market Size of Cancer Cachexia in 7MM in USD Million (2017–2030)
Figure 25: Market Size of Cancer Cachexia in the US, USD Millions (2017–2030)
Figure 26: Market Size of Cancer Cachexia in the US by therapies, USD Millions (2017–2030)
Figure 27: Market Size of Cancer Cachexia in Germany, USD Millions (2017–2030)
Figure 28: Market Size of Cancer Cachexia in Germany by therapies, USD Millions (2017–2030)
Figure 29: Market Size of Cancer Cachexia in France, USD Millions (2017–2030)
Figure 30: Market Size of Cancer Cachexia in France by therapies, USD Millions (2017–2030)
Figure 31: Market Size of Cancer Cachexia in Italy, USD Millions (2017–2030)
Figure 32: Market Size of Cancer Cachexia in Italy by therapies, USD Millions (2017–2030)
Figure 33: Market Size of Cancer Cachexia in Spain, USD Millions (2017–2030)
Figure 34: Market Size of Cancer Cachexia in Spain by therapies, USD Millions (2017–2030)
Figure 35: Market Size of Cancer Cachexia in the UK, USD Millions (2017–2030)
Figure 36: Market Size of Cancer Cachexia in the UK by therapies, USD Millions (2017–2030)
Figure 37: Market Size of Cancer Cachexia in Japan, USD Millions (2017–2030)
Figure 38: Market Size of Cancer Cachexia in Japan by therapies, USD Millions (2017–2030)
Figure 39: Market Drivers
Figure 40:Market Barriers

 

List of Tables


Table 1: Total prevalent cases of Cancer Cachexia in 7MM (2017–2030)
Table 2: Total prevalent cases of Cancer Cachexia in the US (2017–2030)
Table 3: Cancer Cachexia cases based on tumor type in the US (2017–2030)
Table 4: Gender-specific cases of Cancer Cachexia in the US (2017–2030)
Table 5: Total prevalent cases of Cancer Cachexia in Germany (2017–2030)
Table 6: Cancer Cachexia cases based on Tumor Type in Germany (2017–2030)
Table 7: Gender-specific cases of Cancer Cachexia in Germany (2017–2030)
Table 8: Total prevalent cases of Cancer Cachexia in France (2017–2030)
Table 9: Cancer Cachexia cases based on Tumor Type in France (2017–2030)
Table 10: Gender-specific cases of Cancer Cachexia in France (2017–2030)
Table 11: Total prevalent cases of Cancer Cachexia in Italy (2017–2030)
Table 12: Cancer Cachexia cases based on Tumor Type in Italy (2017–2030)
Table 13: Gender-specific cases of Cancer Cachexia in Italy (2017–2030)
Table 14: Total prevalent cases of Cancer Cachexia in Spain (2017–2030)
Table 15: Cancer Cachexia cases based on Tumor Type in Spain (2017–2030)
Table 16: Gender-specific cases of Cancer Cachexia in Spain (2017–2030)
Table 17: Total prevalent cases of Cancer Cachexia in the UK (2017–2030)
Table 18: Cancer Cachexia cases based on tumor type in the UK (2017–2030)
Table 19: Gender-specific cases of Cancer Cachexia in the UK (2017–2030)
Table 20: Total prevalent cases of Cancer Cachexia in Japan (2017–2030)
Table 21: Cancer Cachexia cases based on tumor type in Japan (2017–2030)
Table 22: Gender-specific cases of Cancer Cachexia in Japan (2017–2030)
Table 23: Key cross competition
Table 24: PPP011, Clinical Trial Description, 2020
Table 25: Anamorelin, Clinical Trial Description, 2020
Table 26: Macimorelin, Clinical Trial Description, 2020
Table 27: MT-102, Clinical Trial Description, 2020
Table 28: PF-06946860, Clinical Trial Description, 2020
Table 29: Xilonix plus Onivyde and 5FU, Clinical Trial Description, 2020
Table 30: Cannabics Capsules, Clinical Trial Description, 2020
Table 31: NGM120, Clinical Trial Description, 2020
Table 32: Market Size of Cancer Cachexia in 7MM in USD Million (2017–2030)
Table 33: US Market Size of Cancer Cachexia in USD Million (2017–2030)
Table 34: US Market Size of Cancer Cachexia in USD Million (2017–2030)
Table 35: Market Size of Cancer Cachexia in Germany, USD Millions (2017–2030)
Table 36: Germany Market Size of Cancer Cachexia in USD Million (2017–2030)
Table 37: Market Size of Cancer Cachexia associated in France, USD Millions (2017–2030)
Table 38: France Market Size of Cancer Cachexia in USD Million (2017–2030)
Table 39: Market Size of Cancer Cachexia in Italy, USD Millions (2017–2030)
Table 40: Italy Market Size of Cancer Cachexia in USD Million (2017–2030)
Table 41: Market Size of Cancer Cachexia in Spain, USD Millions (2017–2030)
Table 42: Spain Market Size of Cancer Cachexia in USD Million (2017–2030)
Table 43: Market Size of Cancer Cachexia in the UK, USD Millions (2017–2030)
Table 44: UK Market Size of Cancer Cachexia in USD Million (2017–2030)
Table 45: Market Size of Cancer Cachexia in Japan, USD Millions (2017–2030)
Table 46:Japan Market Size of Cancer Cachexia in USD Million (2017–2030)